NPSC's Director of Operations joins Axol Bioscience's Scientific Advisory Board.

on .


Axol Biosciences Ltd, the Cambridge-based biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, recently announced the appointment of Dr. Paul Andrews, NPSC's Director of Operations to their Scientific Advisory Board (SAB). Paul's appointment follows on from NPSC's ongoing collaborations to use Axol's neural progenitor cells for drug discovery. The other members of the SAB are Chris Torrance (Horizon Discovery), Steve Rees (AstraZeneca), Chas Bountra (SGC/University of Oxford) and Darren Disly (Horizon Discovery Group)

You can read the full press release here.

Read more about Axol Biosciencs here and the other members of the SAB.


NPSC is a facility run and operated by the Universities of Dundee, Edinburgh and Oxford, which are registered UK-based charities. 

Copyright © 2016.